Portal

Portal Biotechnologies is a life sciences company that develops cell engineering and cell analytics solutions for research and clinical applications. The company's proprietary membrane technology uses mechanical disruption (mechanoporation) to enable massive parallelization of intracellular delivery, facilitating the delivery of RNA, gene editing tools, and other molecular cargos into cells. Portal's product suite includes the Gateway, Galaxy, Millibooster, and Galaxy-i platforms, which support multiplexed cargo delivery for drug discovery, cell therapy manufacturing, and AI data generation. The company has secured over 100 customers including 7 of the top 10 pharmaceutical companies and has been awarded an $8M DARPA contract to develop a portable red blood cell engineering device for rapid point-of-care production and treatment. Portal's technology has been validated in peer-reviewed publications including Frontiers in Immunology and the Journal of Immunology. Founded in 2023 and headquartered in Watertown, Massachusetts, Portal has raised $25.7M in Seed funding from investors including Pear VC, Conscience VC, IA Ventures, NFX, 10X Capital, and TechU.